Citius Oncology Q3 FY2026 revenue $1.5M, LYMPHIR demand accelerates

CITIUS ONCOLOGY, INC.

2026-Q3 EPS reported -$0.42 revenue$7,105,197

Revenue $1.5M for Q3 ended June 30, 2026 (vs $0 prior year); $7.1M for nine months.
Net loss $8.9M ($0.08/share) for Q3; $41.1M ($0.42/share) for nine months, incl. $19.7M one-time CMO cancellation charge.
Institutional vial orders grew 31% sequentially to 926 in Q3; July orders 383 vials, largest month; 44 institutions ordering.
Cash $16.6M; received $9.7M from warrant exercises and $10M from first tranche of $25M senior secured term loan.
Appointed Jonathan Peri as independent director; commercial team expanded to 29 professionals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.